Condition
Diabetes Mellitus, Type 2
Locations
Germany
Start date
06/05/2024
Identifiers
Trial ID
NN9388-7782,
NCT number NCT06403761,
Eudract number Not Available
NCT number NCT06403761,
Eudract number Not Available
Summary
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine that combines two medicines called cagrilintide and semaglutide. Doctors may not yet prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a ''dummy'' medicine. Which treatment the participants will get is decided by chance. Participants will get the study medicine together with the current daily diabetes medicine metformin. Participants should not take other medicines for diabetes during the study. The study will last for about 42 weeks.
Trial Overview:
Treatment
DRUG: Semaglutide
DRUG: Cagrilintide
DRUG: Placebo semaglutide
DRUG: Placebo cagrilintide
Study type
INTERVENTIONAL
Trial duration
May 06 2024 - Dec 18 2025
Participants
150
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 75 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.